Curaleaf (OTCMKTS:CURLF – Get Free Report) and Rockwell Medical (NASDAQ:RMTI – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends.
Risk and Volatility
Curaleaf has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500. Comparatively, Rockwell Medical has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500.
Valuation and Earnings
This table compares Curaleaf and Rockwell Medical”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Curaleaf | $1.27 billion | 1.77 | -$231.07 million | ($0.39) | -24.62 |
| Rockwell Medical | $69.26 million | 0.36 | -$5.31 million | ($1.50) | -4.19 |
Rockwell Medical has lower revenue, but higher earnings than Curaleaf. Curaleaf is trading at a lower price-to-earnings ratio than Rockwell Medical, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Curaleaf and Rockwell Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Curaleaf | -7.76% | -8.11% | -2.36% |
| Rockwell Medical | -7.98% | -15.41% | -9.62% |
Institutional & Insider Ownership
0.0% of Curaleaf shares are held by institutional investors. Comparatively, 23.3% of Rockwell Medical shares are held by institutional investors. 4.6% of Rockwell Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Curaleaf and Rockwell Medical, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Curaleaf | 0 | 0 | 1 | 3 | 3.75 |
| Rockwell Medical | 1 | 0 | 1 | 0 | 2.00 |
Rockwell Medical has a consensus price target of $20.00, suggesting a potential upside of 218.47%. Given Rockwell Medical’s higher probable upside, analysts clearly believe Rockwell Medical is more favorable than Curaleaf.
Summary
Curaleaf beats Rockwell Medical on 8 of the 14 factors compared between the two stocks.
About Curaleaf
Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.
About Rockwell Medical
Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.
